196 related articles for article (PubMed ID: 30236546)
21. Demonstration of CDX2 is highly antibody dependant.
Borrisholt M; Nielsen S; Vyberg M
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):64-72. PubMed ID: 22595949
[TBL] [Abstract][Full Text] [Related]
22. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
Milione M
Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
[No Abstract] [Full Text] [Related]
24. Expression of cadherin 17 in well-differentiated neuroendocrine tumours.
Snow AN; Mangray S; Lu S; Clubwala R; Li J; Resnick MB; Yakirevich E
Histopathology; 2015 Jun; 66(7):1010-21. PubMed ID: 25388236
[TBL] [Abstract][Full Text] [Related]
25. Expression of SATB2 in Neuroendocrine Carcinomas of the Lung: Frequent Immunopositivity of Large Cell Neuroendocrine Carcinoma with a Diagnostic Pitfall.
Inoue H; Matsushima J; Kobayashi S; Sairenchi T; Hirata H; Chida M; Ota S; Ban S; Matsumura Y
Int J Surg Pathol; 2022 Apr; 30(2):151-159. PubMed ID: 34913369
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract][Full Text] [Related]
27. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
[TBL] [Abstract][Full Text] [Related]
28. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
[TBL] [Abstract][Full Text] [Related]
29. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
30. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
González I; Lu HC; Sninsky J; Yang C; Bishnupuri K; Dieckgraefe B; Cao D; Chatterjee D
Histopathology; 2019 Oct; 75(4):568-577. PubMed ID: 31077609
[TBL] [Abstract][Full Text] [Related]
31. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
[TBL] [Abstract][Full Text] [Related]
32. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
[TBL] [Abstract][Full Text] [Related]
33. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
34. NKX6-1 Is a Novel Immunohistochemical Marker for Pancreatic and Duodenal Neuroendocrine Tumors.
Tseng IC; Yeh MM; Yang CY; Jeng YM
Am J Surg Pathol; 2015 Jun; 39(6):850-7. PubMed ID: 25871618
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid or neuroendocrine morphology.
Maleki Z
Diagn Cytopathol; 2011 Mar; 39(3):159-67. PubMed ID: 21319315
[TBL] [Abstract][Full Text] [Related]
36. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.
Winn B; Tavares R; Fanion J; Noble L; Gao J; Sabo E; Resnick MB
Hum Pathol; 2009 Mar; 40(3):398-404. PubMed ID: 18992917
[TBL] [Abstract][Full Text] [Related]
37. Recent updates on grading and classification of neuroendocrine tumors.
Kim JY; Hong SM; Ro JY
Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
[TBL] [Abstract][Full Text] [Related]
38. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
Bellizzi AM
Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
[TBL] [Abstract][Full Text] [Related]
39. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
[TBL] [Abstract][Full Text] [Related]
40. High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back.
La Rosa S; Sessa F
Endocr Pathol; 2014 Jun; 25(2):193-8. PubMed ID: 24715269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
